What are the main results from the recent clinical trial by Veradermics (NYSE:MANE)?

Veradermics (NYSE:MANE) reported that female patients taking its VDPHL01 treatment achieved an average increase of up to 23.3 hairs per square centimeter. The company stated that 90.0% of participants on a twice-daily dose reported improved hair coverage after six months.

How fast did the drug by Veradermics (NYSE:MANE) show results in patients?

Veradermics (NYSE:MANE) stated that clinical investigators observed hair growth as early as two months into the trial. At that measured timepoint, 67.2% of patients were graded as demonstrating an improvement in overall hair coverage.

What are the safety observations for the hair loss treatment by Veradermics (NYSE:MANE)?

Veradermics (NYSE:MANE) reported no treatment-related serious adverse events during the six-month study. The company also noted there were no adverse events of special interest related to cardiac origin across the patient groups.

Why is Veradermics (NYSE:MANE) focusing on this specific oral formulation?

Veradermics (NYSE:MANE) is advancing this extended-release formulation to create a reliable alternative to topical over-the-counter options. The company stated it aims for the drug to become the first FDA-approved oral treatment for female pattern hair loss.

What are the upcoming clinical milestones for Veradermics (NYSE:MANE)?

Veradermics (NYSE:MANE) stated it expects to release topline data for its female pattern hair loss Phase 3 study in the first half of 2027. The firm also anticipates Phase 3 trial results for its male cohort in the second half of 2026.

Image for illustrative purposes only. Not a real photo.

Veradermics reports 23.3 hair count increase in trial

Written by Heidi Cuthbert Published Jul 15, 2026, 11:27 AM

Veradermics announced that patients in its Phase 2 clinical trial for VDPHL01 experienced an average increase of up to 23.3 hairs per square centimeter over six months.
The company reported no treatment-related serious adverse events or cardiac issues, supporting the overall safety profile of the oral formulation.
Management stated the results strengthen its conviction in the ongoing Phase 3 trial, with topline data anticipated in the first half of 2027.

Veradermics (NYSE:MANE) reported that its VDPHL01 treatment produced an average increase of up to 23.3 hairs per square centimeter in female patients over six months.

The Phase 2 clinical trial results demonstrated a consistent patient response compared to the historical reliance on topical over-the-counter options and unproven supplements.

The data showed 88.9% of participants on a once-daily 4.5mg dose and 90% on a twice-daily 4.5mg dose reported improved hair coverage.

Following the announcement, Veradermics share price was up at $112.37.

Veradermics stated it is actively recruiting female participants for its extensive pivotal Phase 3 trial to support a potential regulatory approval.

The business also completed enrollment for its second Phase 3 male trial, with management anticipating topline results for that cohort in the second half of 2026.

Veradermics reports 23.3 hair count increase in trial

Frequently asked questions

Assets related to this article